 Shyam Raghavan
Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 21 | 2024 | 855 | 6.950 |
Why?
| | Melanoma | 7 | 2024 | 760 | 3.140 |
Why?
| | Biomarkers, Tumor | 10 | 2024 | 1276 | 1.920 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 4 | 2020 | 10 | 1.680 |
Why?
| | Nevus, Pigmented | 2 | 2024 | 34 | 1.510 |
Why?
| | Antigens, Neoplasm | 4 | 2024 | 319 | 1.480 |
Why?
| | Diagnosis, Differential | 12 | 2024 | 1483 | 1.090 |
Why?
| | Tendons | 5 | 2016 | 111 | 0.990 |
Why?
| | Genes, T-Cell Receptor gamma | 2 | 2021 | 3 | 0.930 |
Why?
| | Merkel cell polyomavirus | 1 | 2024 | 4 | 0.900 |
Why?
| | Carcinoma, Merkel Cell | 1 | 2024 | 17 | 0.880 |
Why?
| | Carcinoma, Basal Cell | 2 | 2022 | 75 | 0.880 |
Why?
| | Nevus | 1 | 2024 | 26 | 0.850 |
Why?
| | Cloning, Molecular | 2 | 2021 | 534 | 0.850 |
Why?
| | Melanocytes | 2 | 2022 | 65 | 0.840 |
Why?
| | Immunohistochemistry | 8 | 2024 | 1738 | 0.840 |
Why?
| | Xeroderma Pigmentosum | 1 | 2022 | 8 | 0.770 |
Why?
| | Hamartoma | 1 | 2022 | 22 | 0.760 |
Why?
| | Granular Cell Tumor | 1 | 2022 | 7 | 0.760 |
Why?
| | Pityriasis Lichenoides | 1 | 2021 | 1 | 0.750 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2021 | 22 | 0.750 |
Why?
| | Pathologists | 1 | 2022 | 18 | 0.740 |
Why?
| | Mycosis Fungoides | 2 | 2018 | 61 | 0.740 |
Why?
| | Tissue Engineering | 5 | 2016 | 423 | 0.730 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2020 | 215 | 0.720 |
Why?
| | Rhabdoid Tumor | 1 | 2022 | 99 | 0.720 |
Why?
| | Lymphoproliferative Disorders | 1 | 2021 | 57 | 0.720 |
Why?
| | Syphilis | 1 | 2021 | 32 | 0.720 |
Why?
| | Bone Neoplasms | 1 | 2024 | 247 | 0.710 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2020 | 17 | 0.700 |
Why?
| | Lymphoid Enhancer-Binding Factor 1 | 1 | 2020 | 6 | 0.690 |
Why?
| | Carcinoma | 1 | 2022 | 240 | 0.680 |
Why?
| | Sarcoma, Clear Cell | 1 | 2020 | 10 | 0.680 |
Why?
| | Keratin-7 | 1 | 2020 | 3 | 0.680 |
Why?
| | Eyelid Neoplasms | 1 | 2020 | 10 | 0.680 |
Why?
| | Carcinoma, Signet Ring Cell | 1 | 2020 | 15 | 0.670 |
Why?
| | Immunocompromised Host | 1 | 2021 | 202 | 0.650 |
Why?
| | Skin Diseases | 1 | 2021 | 149 | 0.650 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2019 | 11 | 0.630 |
Why?
| | Oligodendrocyte Transcription Factor 2 | 1 | 2019 | 21 | 0.630 |
Why?
| | Receptors, Androgen | 1 | 2020 | 150 | 0.610 |
Why?
| | Ki-1 Antigen | 1 | 2018 | 4 | 0.610 |
Why?
| | Skin | 5 | 2024 | 752 | 0.590 |
Why?
| | Cadherins | 1 | 2020 | 206 | 0.590 |
Why?
| | Ki-67 Antigen | 1 | 2018 | 112 | 0.590 |
Why?
| | Humans | 57 | 2024 | 137585 | 0.570 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 43 | 0.560 |
Why?
| | Exanthema | 3 | 2023 | 78 | 0.540 |
Why?
| | Antigens, CD | 1 | 2020 | 521 | 0.540 |
Why?
| | Tissue Scaffolds | 4 | 2016 | 211 | 0.520 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 327 | 0.510 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2024 | 224 | 0.490 |
Why?
| | Kidney Transplantation | 1 | 2021 | 708 | 0.460 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2018 | 528 | 0.440 |
Why?
| | Mastectomy | 1 | 2015 | 137 | 0.440 |
Why?
| | Skin Abnormalities | 2 | 2023 | 12 | 0.420 |
Why?
| | Aged | 14 | 2024 | 23961 | 0.410 |
Why?
| | Cell Proliferation | 2 | 2020 | 2475 | 0.410 |
Why?
| | Mammaplasty | 1 | 2015 | 105 | 0.410 |
Why?
| | Female | 29 | 2024 | 73304 | 0.390 |
Why?
| | Foot | 2 | 2023 | 96 | 0.380 |
Why?
| | Aged, 80 and over | 9 | 2024 | 7635 | 0.380 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2012 | 39 | 0.380 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2012 | 87 | 0.370 |
Why?
| | Appendix | 1 | 2021 | 30 | 0.360 |
Why?
| | Male | 23 | 2024 | 67762 | 0.360 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2021 | 38 | 0.360 |
Why?
| | Mutation | 5 | 2024 | 3958 | 0.350 |
Why?
| | Adipose Tissue | 2 | 2013 | 635 | 0.350 |
Why?
| | Stem Cells | 2 | 2013 | 594 | 0.350 |
Why?
| | Drug Eruptions | 2 | 2020 | 27 | 0.350 |
Why?
| | DNA Mutational Analysis | 2 | 2024 | 399 | 0.350 |
Why?
| | Stomach Neoplasms | 1 | 2021 | 122 | 0.330 |
Why?
| | Duodenum | 3 | 2024 | 78 | 0.320 |
Why?
| | Postoperative Complications | 1 | 2021 | 2654 | 0.320 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2012 | 319 | 0.320 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2021 | 539 | 0.300 |
Why?
| | Middle Aged | 15 | 2024 | 33479 | 0.300 |
Why?
| | Fibroblasts | 1 | 2012 | 996 | 0.260 |
Why?
| | Intestinal Diseases | 2 | 2024 | 42 | 0.250 |
Why?
| | Celiac Disease | 3 | 2024 | 294 | 0.250 |
Why?
| | Pancreatic Neoplasms | 2 | 2024 | 938 | 0.240 |
Why?
| | Prognosis | 3 | 2024 | 4030 | 0.240 |
Why?
| | Soft Tissue Neoplasms | 2 | 2021 | 115 | 0.230 |
Why?
| | Antigens, Viral, Tumor | 1 | 2024 | 7 | 0.230 |
Why?
| | Hematoxylin | 1 | 2024 | 6 | 0.230 |
Why?
| | Eosine Yellowish-(YS) | 1 | 2024 | 10 | 0.230 |
Why?
| | Extremities | 2 | 2024 | 131 | 0.220 |
Why?
| | Polyomavirus Infections | 1 | 2024 | 31 | 0.220 |
Why?
| | Adult | 13 | 2023 | 37929 | 0.220 |
Why?
| | Necrobiosis Lipoidica | 1 | 2023 | 2 | 0.210 |
Why?
| | Livedo Reticularis | 1 | 2023 | 4 | 0.210 |
Why?
| | Tattooing | 1 | 2023 | 14 | 0.210 |
Why?
| | Leg | 2 | 2023 | 236 | 0.210 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2024 | 289 | 0.210 |
Why?
| | Esophagogastric Junction | 1 | 2022 | 51 | 0.200 |
Why?
| | Comparative Genomic Hybridization | 1 | 2022 | 30 | 0.190 |
Why?
| | Retrospective Studies | 6 | 2024 | 15657 | 0.190 |
Why?
| | Child, Preschool | 6 | 2024 | 11074 | 0.190 |
Why?
| | Insulins | 1 | 2023 | 37 | 0.190 |
Why?
| | Child | 8 | 2024 | 21935 | 0.190 |
Why?
| | S100 Proteins | 1 | 2022 | 37 | 0.190 |
Why?
| | Uveitis, Anterior | 1 | 2021 | 18 | 0.180 |
Why?
| | Lymphoma, T-Cell | 1 | 2021 | 25 | 0.180 |
Why?
| | Lymphoma, Primary Cutaneous Anaplastic Large Cell | 1 | 2021 | 1 | 0.180 |
Why?
| | Mesenchymoma | 1 | 2021 | 8 | 0.180 |
Why?
| | Pemphigus | 1 | 2021 | 8 | 0.180 |
Why?
| | DNA Helicases | 1 | 2022 | 145 | 0.180 |
Why?
| | Erythema | 1 | 2021 | 29 | 0.180 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2021 | 18 | 0.180 |
Why?
| | Liposarcoma, Myxoid | 1 | 2021 | 10 | 0.180 |
Why?
| | Transcription Factor CHOP | 1 | 2021 | 31 | 0.180 |
Why?
| | Nevus, Blue | 1 | 2020 | 2 | 0.170 |
Why?
| | Dysplastic Nevus Syndrome | 1 | 2020 | 2 | 0.170 |
Why?
| | Lymphoma, B-Cell | 1 | 2022 | 106 | 0.170 |
Why?
| | Scrotum | 1 | 2020 | 27 | 0.170 |
Why?
| | Phospholipids | 1 | 2022 | 223 | 0.170 |
Why?
| | Biopsy | 2 | 2024 | 1129 | 0.170 |
Why?
| | Histiocytes | 1 | 2020 | 7 | 0.170 |
Why?
| | Smooth Muscle Tumor | 1 | 2020 | 6 | 0.170 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2020 | 48 | 0.170 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2020 | 71 | 0.170 |
Why?
| | Adolescent | 6 | 2022 | 21513 | 0.160 |
Why?
| | Combined Modality Therapy | 2 | 2020 | 1236 | 0.160 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2020 | 220 | 0.160 |
Why?
| | Ehlers-Danlos Syndrome | 1 | 2019 | 15 | 0.160 |
Why?
| | Hodgkin Disease | 1 | 2021 | 138 | 0.160 |
Why?
| | Paired Box Transcription Factors | 1 | 2019 | 46 | 0.160 |
Why?
| | Immunoglobulin Light-chain Amyloidosis | 1 | 2019 | 7 | 0.160 |
Why?
| | Myositis, Inclusion Body | 1 | 2019 | 11 | 0.160 |
Why?
| | Intestinal Perforation | 1 | 2019 | 46 | 0.150 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2020 | 161 | 0.150 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2020 | 77 | 0.150 |
Why?
| | Surgical Flaps | 1 | 2020 | 130 | 0.150 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2022 | 279 | 0.150 |
Why?
| | Eosinophilic Esophagitis | 1 | 2023 | 325 | 0.150 |
Why?
| | Sjogren's Syndrome | 1 | 2019 | 54 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 190 | 0.150 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 267 | 0.150 |
Why?
| | beta Catenin | 1 | 2020 | 253 | 0.150 |
Why?
| | Tumor Suppressor Proteins | 1 | 2020 | 327 | 0.140 |
Why?
| | Nuclear Proteins | 1 | 2022 | 712 | 0.140 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2020 | 252 | 0.140 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2020 | 434 | 0.130 |
Why?
| | Proto-Oncogene Proteins | 1 | 2020 | 648 | 0.130 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 460 | 0.130 |
Why?
| | Hospitals, County | 1 | 2016 | 11 | 0.130 |
Why?
| | Pericardium | 1 | 2016 | 55 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 683 | 0.130 |
Why?
| | Wrist Injuries | 1 | 2016 | 23 | 0.130 |
Why?
| | Carrier Proteins | 1 | 2020 | 771 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1079 | 0.120 |
Why?
| | Peripheral Nerve Injuries | 1 | 2016 | 36 | 0.120 |
Why?
| | Lacerations | 1 | 2016 | 35 | 0.120 |
Why?
| | Sensitivity and Specificity | 1 | 2020 | 1946 | 0.120 |
Why?
| | Cohort Studies | 3 | 2024 | 5742 | 0.120 |
Why?
| | Organ Sparing Treatments | 1 | 2015 | 34 | 0.120 |
Why?
| | RNA | 1 | 2022 | 921 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 804 | 0.120 |
Why?
| | Lower Extremity | 3 | 2023 | 427 | 0.120 |
Why?
| | Pakistan | 2 | 2024 | 76 | 0.110 |
Why?
| | Zambia | 2 | 2024 | 57 | 0.110 |
Why?
| | Intestinal Mucosa | 3 | 2024 | 623 | 0.110 |
Why?
| | Transcription Factors | 1 | 2022 | 1719 | 0.110 |
Why?
| | Breast | 1 | 2015 | 151 | 0.110 |
Why?
| | Microvessels | 1 | 2015 | 88 | 0.110 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1430 | 0.100 |
Why?
| | Transcriptome | 1 | 2019 | 971 | 0.100 |
Why?
| | T-Lymphocytes | 1 | 2020 | 1996 | 0.090 |
Why?
| | Patient Compliance | 1 | 2016 | 581 | 0.090 |
Why?
| | Inflammation | 1 | 2023 | 2837 | 0.090 |
Why?
| | Polymers | 2 | 2023 | 490 | 0.090 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 345 | 0.090 |
Why?
| | Bioreactors | 1 | 2011 | 42 | 0.090 |
Why?
| | Collagen | 1 | 2013 | 452 | 0.090 |
Why?
| | Drug Synergism | 1 | 2012 | 382 | 0.090 |
Why?
| | Rats, Wistar | 1 | 2011 | 455 | 0.080 |
Why?
| | Rabbits | 1 | 2011 | 794 | 0.080 |
Why?
| | Extracellular Matrix | 2 | 2024 | 528 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 674 | 0.080 |
Why?
| | Vascular Surgical Procedures | 2 | 2009 | 303 | 0.080 |
Why?
| | Vascular Neoplasms | 1 | 2009 | 18 | 0.080 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2009 | 25 | 0.080 |
Why?
| | Angioplasty | 1 | 2009 | 47 | 0.080 |
Why?
| | Prospective Studies | 3 | 2023 | 7604 | 0.080 |
Why?
| | Esophagus | 1 | 2021 | 255 | 0.080 |
Why?
| | Treatment Outcome | 3 | 2020 | 10811 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 2129 | 0.080 |
Why?
| | Colon | 1 | 2021 | 282 | 0.080 |
Why?
| | Young Adult | 4 | 2020 | 13209 | 0.070 |
Why?
| | Polyethyleneimine | 1 | 2008 | 18 | 0.070 |
Why?
| | Vaccines, DNA | 1 | 2008 | 32 | 0.070 |
Why?
| | Microspheres | 1 | 2008 | 137 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2013 | 4193 | 0.070 |
Why?
| | Sarcoma | 1 | 2009 | 188 | 0.070 |
Why?
| | Education, Medical, Undergraduate | 1 | 2009 | 188 | 0.070 |
Why?
| | Animals | 6 | 2023 | 36940 | 0.060 |
Why?
| | Computer Simulation | 1 | 2009 | 978 | 0.060 |
Why?
| | Goblet Cells | 1 | 2024 | 22 | 0.060 |
Why?
| | Child Nutrition Disorders | 1 | 2024 | 20 | 0.060 |
Why?
| | Bangladesh | 1 | 2024 | 56 | 0.060 |
Why?
| | Milk Proteins | 1 | 2023 | 34 | 0.050 |
Why?
| | Antigen-Antibody Complex | 1 | 2023 | 90 | 0.050 |
Why?
| | Intestine, Small | 1 | 2024 | 156 | 0.050 |
Why?
| | Acrylamides | 1 | 2023 | 57 | 0.050 |
Why?
| | Risk Assessment | 1 | 2021 | 3457 | 0.050 |
Why?
| | Clinical Competence | 1 | 2009 | 1118 | 0.050 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2022 | 83 | 0.050 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2021 | 42 | 0.040 |
Why?
| | Hyperplasia | 1 | 2022 | 175 | 0.040 |
Why?
| | In Situ Hybridization | 1 | 2022 | 316 | 0.040 |
Why?
| | Hepatocytes | 1 | 2022 | 220 | 0.040 |
Why?
| | Genes, T-Cell Receptor | 1 | 2020 | 9 | 0.040 |
Why?
| | CD4-CD8 Ratio | 1 | 2020 | 22 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2022 | 105 | 0.040 |
Why?
| | Lip | 1 | 2020 | 24 | 0.040 |
Why?
| | Cattle | 1 | 2023 | 984 | 0.040 |
Why?
| | Peripheral Nerves | 1 | 2020 | 65 | 0.040 |
Why?
| | Infant | 2 | 2024 | 9465 | 0.040 |
Why?
| | Genetic Therapy | 1 | 2022 | 297 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2021 | 390 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 317 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2021 | 160 | 0.040 |
Why?
| | Allergens | 1 | 2023 | 409 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2021 | 318 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 552 | 0.040 |
Why?
| | Ileostomy | 1 | 2019 | 20 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2020 | 352 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2022 | 591 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2023 | 893 | 0.040 |
Why?
| | Colectomy | 1 | 2019 | 100 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2022 | 1060 | 0.040 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2021 | 242 | 0.040 |
Why?
| | Machine Learning | 1 | 2023 | 493 | 0.030 |
Why?
| | Mice | 3 | 2023 | 17787 | 0.030 |
Why?
| | Synoviocytes | 1 | 2016 | 16 | 0.030 |
Why?
| | San Francisco | 1 | 2016 | 52 | 0.030 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2016 | 201 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1060 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 2031 | 0.030 |
Why?
| | Hydrogels | 1 | 2023 | 678 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 346 | 0.030 |
Why?
| | Psychology | 1 | 2016 | 85 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 976 | 0.030 |
Why?
| | Aftercare | 1 | 2016 | 208 | 0.030 |
Why?
| | Rats | 1 | 2023 | 5647 | 0.030 |
Why?
| | Swine | 1 | 2016 | 775 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2734 | 0.030 |
Why?
| | Liver | 1 | 2022 | 1943 | 0.030 |
Why?
| | Cell Survival | 1 | 2016 | 1120 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2013 | 239 | 0.030 |
Why?
| | Disease Progression | 1 | 2020 | 2757 | 0.020 |
Why?
| | Recovery of Function | 1 | 2016 | 653 | 0.020 |
Why?
| | Social Support | 1 | 2016 | 618 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2016 | 1289 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2022 | 5757 | 0.020 |
Why?
| | Tensile Strength | 1 | 2011 | 97 | 0.020 |
Why?
| | Mental Health Services | 1 | 2016 | 421 | 0.020 |
Why?
| | Elastic Modulus | 1 | 2011 | 123 | 0.020 |
Why?
| | Problem-Based Learning | 1 | 2009 | 92 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2009 | 183 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2011 | 810 | 0.020 |
Why?
| | Career Choice | 1 | 2009 | 219 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3566 | 0.020 |
Why?
| | United States | 1 | 2024 | 14841 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2008 | 325 | 0.020 |
Why?
| | Educational Measurement | 1 | 2009 | 289 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5131 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2009 | 512 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 1991 | 0.020 |
Why?
| | Biomarkers | 1 | 2016 | 4149 | 0.010 |
Why?
| | Students, Medical | 1 | 2009 | 348 | 0.010 |
Why?
| | Drug Delivery Systems | 1 | 2008 | 365 | 0.010 |
Why?
| | Kinetics | 1 | 2008 | 1670 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2008 | 1178 | 0.010 |
Why?
| | Curriculum | 1 | 2009 | 992 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2847 | 0.010 |
Why?
|
|
Raghavan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|